KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Research & Development (2016 - 2026)

Bristol Myers Squibb has reported Research & Development over the past 18 years, most recently at $2.6 billion for Q1 2026.

  • Quarterly Research & Development rose 17.37% to $2.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.3 billion through Mar 2026, down 3.53% year-over-year, with the annual reading at $10.0 billion for FY2025, 10.83% down from the prior year.
  • Research & Development was $2.6 billion for Q1 2026 at Bristol Myers Squibb, up from $2.6 billion in the prior quarter.
  • Over five years, Research & Development peaked at $3.2 billion in Q4 2024 and troughed at $2.2 billion in Q3 2023.
  • The 5-year median for Research & Development is $2.5 billion (2023), against an average of $2.5 billion.
  • Year-over-year, Research & Development increased 28.77% in 2024 and then dropped 18.96% in 2025.
  • A 5-year view of Research & Development shows it stood at $2.5 billion in 2022, then dropped by 1.27% to $2.5 billion in 2023, then increased by 28.77% to $3.2 billion in 2024, then dropped by 18.96% to $2.6 billion in 2025, then rose by 2.44% to $2.6 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Research & Development are $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.5 billion (Q3 2025).